Aim To determine the effect of roselle (Hibiscus sabdariffa) petals in dextran sodium sulfate (DSS)-induced colitis model by measuring pro-inflammatory cytokines expressions (IL-6, and TNF-α), anti-inflammatory cytokine expression (IL-10) and histological colitis inflammation score (HCIS). Methods This study was conducted in two phases. For the first phase, five DSS-induced colitis mice were sacrificed (group 1) and compared with six healthy mice (group 2) after five-cycle induction (70 days). For the second phase, roselle-treated DSS-induced colitis mice were sacrificed on day 7, 14, 21, and 28 after induction and compared with mesalazine-treated DSS-induced colitis mice. Expressions of IL-6, TNF-α, and IL-10 were determined by immunohistochemistry and HCIS were assessed by two experienced pathologists. Results The expressions of IL-6, TNF-α, and IL-10, and HCIS in DSS-induced colitis mice were increased compared with control. The expressions of IL-6, TNF-α were significantly higher in roselle-treated group on day 7 and 14, but not on day 21 and 28, whereas, the expression of IL-10 was significantly lower only on day 7 compared with mesalazine-treated group. The inflammation was higher in roselle-treated group assessed by using HCIS. Compared to day 0, the reduction of HCIS was significant in roselle-treated and mesalazine-treated groups. Conclusion Roselle flower petal can attenuate the inflammation in DSS-induced colitis in mice. The extract of roselle can be given as an adjuvant therapy to the first-line therapy to enhance anti-inflammatory effect by increasing expression of anti-inflammatory cytokines and decreasing pro-inflammatory cytokines.
Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018. p. 305–53.
2.
Sun M, He C, Cong Y, Liu Z. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. Mucosal Immunol. 2015. p. 969–78.
3.
Bamias G, Kaltsa G, Ladas S. Cytokines in the pathogenesis of ulcerative colitis. Discovery Medicine. 2011. p. 459–67.
4.
Műzes G, Molnár B, Tulassay Z, Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol. 2012. p. 5848–61.
5.
Strober W, Fuss I. Pro-inflammatory cytokines in the pathogenesis of IBD. Gastroenterology. 2011. p. 1756–67.
6.
Barman S, Kayama H, Okuzaki D, Ogino T, Osawa H, Matsuno H, et al. Identification of a human intestinal myeloid cell subset that regulates gut homeostasis. Int Immunol. 2016. p. 533–45.
7.
Keubler L, Buettner M, Häger C, Bleich A. A multihit model: colitis lessons from the interleukin-10-deficient mouse. Inflamm Bowel Dis. 2015. p. 1967–75.
8.
Liu B, Tonkonogy S, Sartor R. Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology. 2011. p. 653–62.
9.
Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011. p. 237–48.
10.
Nielsen O, Seidelin J, Munck L, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011. p. 15–28.
11.
Zhang H, Wang L, Li C, Yu Y, Yi Y, Wang J, et al. Exosome-induced regulation in inflammatory bowel disease. Front Immunol. 2019. p. 1464.
12.
Da-Costa-Rocha I, Bonnlaender B, Sievers H, Pischel I, Heinrich M. Hibiscus sabdariffa L. -A phytochemical and pharmacological review. Food Chem. 2014. p. 424–43.
13.
Ilodibia C, Achebe U, Arubalueze C, Ibeh E. A comparative study on morphology, mineral and vitamin compositions of two variants of Hibiscus sabdariffa (L.). Arch Agri Environ Sci. 2019. p. 50–6.
14.
Anokwuru C, Esiaba I, Ajbaye O, Adesuyi A. Polyphenolic content and antioxidant activity of hibiscus sabdariffa calyx. Res J Med Plant. 2011. p. 557–66.
15.
Chang YC, Huang HP, Hsu JD, Yang SF, Wang CJ. Hibiscus anthocyanins rich extract-induced apoptotic cell death in human promyelocytic leukemia cells. Toxicol Appl Pharm. 2005. p. 201–12.
16.
Fakeye T, Pal A, Khanuja S. Anxiolytic and sedative effects of extracts of Hibiscus sabdariffa Linn (family Malvaceae). Afr J Med Med Sci. 2008. p. 49–54.
17.
Xu Q, Katakura Y, Yamashita M, Fang S, Tamura T, Matsumoto S, et al. IL-10 augments antibody production in in vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation. Biosci Biotech Bioch. 2004. p. 2279–84.
18.
Laurence D, Bacharach A. Evaluation of drug activities: pharmacometrics. Academic Press Inc. Ltd; 1964.
19.
Laroui H, Ingersoll S, Liu H, Baker M, Ayyadurai S, Charania M, et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS one. 2012. p. 32084.
20.
Jammal M, Da Silva A, A, Filho M, De Castro Côbo A, Adad E, et al. Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms. Oncol Lett. 2015. p. 979–83.
21.
Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007. p. 514–21.
22.
Eichele D, Kharbanda K. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol. 2017. p. 6016–29.
23.
Yuan B, Zhou S, Lu Y, Liu J, Wan J, Wang H, et al. Changes in the expression and distribution of claudins, increased epithelial apoptosis, and a mannan-binding lectin-associated immune response lead to barrier dysfunction in dextran sodium sulfate-induced rat colitis. Gut Liver. 2015. p. 734–40.
24.
Poritz L, Garver K, Green C, Fitzpatrick L, Ruggiero F, Koltun W. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res. 2007. p. 12–9.
25.
Fakeye T. Toxicity and immunomodulatory activity of fractions of Hibiscus sabdariffa Linn (family Malvaceae) in animal models. Afr J Tradit Complem. 2008. p. 394–8.
26.
Ham M, Moss A. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012. p. 113–23.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
